Search Result

Results for "

cyclin D1

" in MCE Product Catalog:

By Targets:	CDK (20) Akt (2) Apoptosis (15) ATM/ATR (1) Aurora Kinase (1) Autophagy (5) Bcl-2 Family (3) Casein Kinase (1) Caspase (1) CXCR (1) Deubiquitinase (2) Endogenous Metabolite (1) Eukaryotic Initiation Factor (eIF) (1) FLT3 (1) FXR (1) GSK-3 (5) HDAC (1) JAK (2) JNK (1) Keap1-Nrf2 (1) MDM-2/p53 (2) MEK (2) NF-κB (1) P-glycoprotein (1) PAK (1) Parasite (2) PKC (1) RAR/RXR (1) Reactive Oxygen Species (1) STAT (3) Wnt (1) β-catenin (2)
By Research Areas:	Cancer (42) Infection (3) Inflammation/Immunology (3) Neurological Disease (3)

By Targets:

CDK (20)

Akt (2)

Apoptosis (15)

ATM/ATR (1)

Aurora Kinase (1)

Autophagy (5)

Bcl-2 Family (3)

Casein Kinase (1)

Caspase (1)

CXCR (1)

Deubiquitinase (2)

Endogenous Metabolite (1)

Eukaryotic Initiation Factor (eIF) (1)

FLT3 (1)

FXR (1)

GSK-3 (5)

HDAC (1)

JAK (2)

JNK (1)

Keap1-Nrf2 (1)

MDM-2/p53 (2)

MEK (2)

NF-κB (1)

P-glycoprotein (1)

PAK (1)

Parasite (2)

PKC (1)

RAR/RXR (1)

Reactive Oxygen Species (1)

STAT (3)

Wnt (1)

β-catenin (2)

By Research Areas:

Cancer (42)

Infection (3)

Inflammation/Immunology (3)

Neurological Disease (3)

Inhibitors & Agonists

Natural
Products

Recombinant Proteins

Antibodies

Targets Recommended: Cyclin G-associated Kinase (GAK) CDK

Cat. No.	Product Name	Target	Research Areas

HY-139450

PF-07220060 CDK4/6-IN-6	CDK	Cancer
PF-07220060 (CDK4/6-IN-6; example A94) is a potent CDK4/CDK6 inhibitor with a K_i of 0.6 nM and 13.9 nM for CDK4/Cyclin D1 and CDK6/Cyclin D3, respectively.

HY-145669

DIF-3	CDK GSK-3	Cancer
DIF-3 reduces the expression levels of cyclin D1 and c-Myc by facilitating their degradation via activation of GSK-3β. DIF-3 inhibits Wnt/β-catenin signaling pathway-related proteins in DLD-1 cells. DIF-3 exerts a strong antiproliferative effect on the human cervical cancer cell line HeLa by inducing cyclin D1 degradation and inhibiting cyclin D1 mRNA expression.

HY-147651

β-catenin-IN-4	β-catenin	Cancer
β-catenin-IN-4 (Compound 39) is a β-catenin inhibitor with a K_i of 0.64 μM. β-catenin-IN-4 reduces the protein expression levels of cyclin D1 and c-Myc.

HY-146389

Anticancer agent 50	MDM-2/p53 P-glycoprotein	Cancer
Anticancer agent 50 (compound 6) is a potent ABCB1 efflux pump modulator. Anticancer agent 50 shows cytotoxic effects and antiproliferative effects. Anticancer agent 50 decreases the expression of cyclin D1 and induces p53 expression. Anticancer agent 50 has the potential for the research of T-lymphoma.

HY-120458

LCAHA LCA hydroxyamide	Deubiquitinase	Cancer
LCAHA (LCA hydroxyamide) is a deubiquitinase USP2a inhibitor with IC₅₀s of 9.7 μM and 3.7μM in Ub-AMC Assay and Di-Ub Assay, respectively. LCAHA destabilizes Cyclin D1 and induces G0/G1 arrest by inhibiting deubiquitinase USP2a.

HY-108907

SR-1277	Casein Kinase	Cancer
SR-1277 is a potent, selective and ATP competitive CK1δ/ε inhibitor, with IC₅₀s of 49 nM and 260 nM, respectively. SR-1277 also inhibits FLT3, CDK4/cyclin D1, CDK6/cyclin D3 and CDK9/cyclin K, with IC₅₀s of 305 nM, 1340 nM, 311 nM and 109 nM, respectively. SR-1277 can be used for the research of cancer.

HY-125035

LCH-7749944 GNF-PF-2356	PAK Apoptosis	Cancer
LCH-7749944 (GNF-PF-2356) is a potent PAK4 inhibitor with an IC₅₀ of 14.93 μM. LCH-7749944 effectively suppresses the proliferation of human gastric cancer cells through downregulation of PAK4/c-Src/EGFR/cyclin D1 pathway and induces apoptosis.

HY-111361

FN-1501	CDK FLT3	Cancer
FN-1501 is a potent inhibitor of FLT3 and CDK, with IC₅₀s of 2.47, 0.85, 1.96, and 0.28 nM for CDK2/cyclin A, CDK4/cyclin D1, CDK6/cyclin D1 and FLT3, respectively. FN-1501 has anticancer activity.

HY-12352

HJC0416	STAT Apoptosis	Cancer
HJC0416 is a potent and orally active STAT3 inhibitor. HJC0416 shows antiprolifeative activity and induces apoptosis. HJC0416 decreases the expression of p-STAT3 (Tyr-705), Cyclin D1 and increases the expression of cleaved caspase-3 protein. HJC0416 shows anti-tumor activity.

HY-115932

Aurora kinase-IN-1	Aurora Kinase Apoptosis	Cancer
Aurora kinase-IN-1 (Compound 9) is a potent inhibitor of aurora kinase. Aurora kinase-IN-1 upregulates the expression of G1 cell cycle inhibitory proteins including p21 and p27, and G1 progressive cyclin D1, and downregulates G1-to-S progressive cyclins, resulting in cell cycle arrest at the G1/S boundary. Aurora kinase-IN-1 also induces apoptosis. Aurora kinase-IN-1 is a lead compound for chemotherapeutic agents.

HY-112822

ON-013100
CDK Cancer

ON-013100, an antineoplastic agent, acts a mitotic inhibitor that could inhibit Cyclin D1 expression.

ON-013100	CDK	Cancer
ON-013100, an antineoplastic agent, acts a mitotic inhibitor that could inhibit Cyclin D1 expression.

HY-N4327

Eurycomalactone	NF-κB Apoptosis Akt Bcl-2 Family	Infection Inflammation/Immunology
Eurycomalactone is an active quassinoid could be isolated from Eurycoma longifolia Jack. Eurycomalactone is a potent NF-κB inhibitor with an IC₅₀ value of 0.5 μM. Eurycomalactone inhibits protein synthesis and depletes cyclin D1. Eurycomalactone enhances radiosensitivity through arrest cell cycle at G2/M phase and delayed DNA double-strand break repair. Eurycomalactone inhibits the activation of AKT/NF‑κB signaling, induces apoptosis and enhances chemosensitivity to Cisplatin (HY-17394).

HY-136726

CGP-82996 CINK4	CDK	Cancer
GP-82996 (CINK4) is a pharmacological inhibitor of CDK4/6. GP-82996 has IC₅₀s of 1.5, 5.6 and 25 μM for CDK4/cyclin D1, CDK6/cyclin D1 and Cdk5/p35, respectively. GP-82996 induces the apoptosis of cancer cells U2OS. GP-82996 can be used in the research of cancer.

HY-10014

R547	CDK GSK-3 Apoptosis	Cancer
R547 is a potent, selective and orally active ATP-competitive CDK inhibitor, with K_is of 2 nM, 3 nM and 1 nM for CDK1/cyclin B, CDK2/cyclin E and CDK4/cyclin D1, respectively.

HY-111207

CA224	CDK Apoptosis	Cancer
CA224 (Compound 1) is a selective and orally active Cdk4–cyclin D1 inhibitor with an IC₅₀ of 6.2 µM. CA224 induces cell apoptosis and shows antitumor activity.

HY-18299A

Purvalanol A NG-60	CDK Autophagy Apoptosis	Cancer
Purvalanol A is a potent CDK inhibitor, which inhibits cdc2-cyclin B, cdk2-cyclin A, cdk2-cyclin E, cdk4-cyclin D1, and cdk5-p35 with IC₅₀s of 4, 70, 35, 850, 75 nM, resepctively.

HY-139449

CDK4/6-IN-5	CDK	Cancer
CDK4/6-IN-5 is a potent CDK4 and CDK6 inhibitor with K_is of 0.2 and 4.4 nM for CDK4/Cyclin D1 and CDK6/Cyclin D3, respectively. (from patent WO2019207463A1 example A93).

HY-103380

NSC 625987
CDK Cancer

NSC 625987 is a specific and high-affinity CDK4 inhibitor with an IC₅₀ of 0.2 μM for CDK4:cyclin D1. NSC 625987 shows >500-fold selectivity for CDK4 over CDK2.

NSC 625987	CDK	Cancer
NSC 625987 is a specific and high-affinity CDK4 inhibitor with an IC₅₀ of 0.2 μM for CDK4:cyclin D1. NSC 625987 shows >500-fold selectivity for CDK4 over CDK2.

HY-10424

Milciclib PHA-848125	CDK Autophagy	Cancer
Milciclib (PHA-848125) is a potent, ATP-competitive and dual inhibitor of CDK and Tropomyosin receptor kinase (TRK), with IC₅₀s of 45, 150, 160, 363, 398 nM and 53 nM for cyclin A/CDK2, cyclin H/CDK7, cyclin D1/CDK4, cyclin E/CDK2, cyclin B/CDK1 and TRKA, respectively.

HY-147409

Ulecaciclib	CDK	Cancer
Ulecaciclib is an orally activitive inhibitor of cyclin-dependent kinase (CDK), with K_i values of 0.62 μM (CDK2/Cyclin A), 0.2 nM (CDK4/Cyclin D1), 3 nM (CDK6/Cyclin D3), and 0.63 μM (CDK7/Cyclin H), respectively. Ulecaciclib can cross blood brain barrier and has good pharmacokinetic characteristics.

HY-N0815

Resibufogenin Bufogenin; Recibufogenin	Others	Cancer
Resibufogenin, a component of huachansu, has been shown to exhibit the anti-proliferative effect against cancer cells, and this may be attributed to the degradation of cyclin D1 caused by the activation of GSK-3β.

HY-115992

CDK4/6-IN-9	CDK	Cancer
CDK4/6-IN-9 (compound 10) is a selective CDK4/6 inhibitor with an IC₅₀ of 905 nM for CDK6/cyclin D1. CDK4/6-IN-9 has the potential for multiple myeloma (MM) research.

HY-111932

Indirubin-5-sulfonate	CDK GSK-3	Cancer
Indirubin-5-sulfonate is a cyclin-dependent kinase (CDK) inhibitor, with IC₅₀ values of 55 nM, 35 nM, 150 nM, 300 nM and 65 nM for CDK1/cyclin B, CDK2/cyclin A, CDK2/cyclin E, CDK4/cyclin D1, and CDK5/p35, respectively. Indirubin-5-sulfonate also shows inhibitory activity against GSK-3β.

HY-16559A

Riviciclib P276-00 free base	CDK	Cancer
Riviciclib (P276-00 free base) is a potent cyclin-dependent kinase (CDK) inhibitor, which inhibits CDK9-cyclinT1, CDK4-cyclin D1, and CDK1-cyclinB with IC₅₀s of 20 nM, 63 nM, and 79 nM, respectively. Riviciclib shows antitumor activity on cisplatin-resistant cells.

HY-16559

Riviciclib hydrochloride P276-00	CDK Apoptosis	Cancer
Riviciclib hydrochloride (P276-00) is a potent cyclin-dependent kinase (CDK) inhibitor, which inhibits CDK9-cyclinT1, CDK4-cyclin D1, and CDK1-cyclinB with IC₅₀s of 20 nM, 63 nM, and 79 nM, respectively. Riviciclib hydrochloride (P276-00) shows antitumor activity on cisplatin-resistant cells.

HY-112799

DK419	Wnt β-catenin	Cancer
DK419 is a potent and orally active Wnt/β-catenin signaling inhibitor, with an IC₅₀ of 0.19 μM. DK419 reduces protein lelvels of Axin2, β-catenin, c-Myc, Cyclin D1 and Survivin and induces production of pAMPK.

HY-15504A

RGB-286638 free base	CDK GSK-3 MEK JAK	Cancer
RGB-286638 is a CDK inhibitor that inhibits the kinase activity of cyclin T1-CDK9, cyclin B1-CDK1, cyclin E-CDK2, **cyclin D1-CDK4*, cyclin* E-CDK3, and p35-CDK5 with IC₅₀s of 1, 2, 3, 4, 5 and 5 nM, respectively; also inhibits GSK-3β, TAK1, Jak2 and MEK1, with IC₅₀s of 3, 5, 50, and 54 nM.

HY-15504

RGB-286638	CDK GSK-3 MEK JAK	Cancer
RGB-286638 is a CDK inhibitor that inhibits the kinase activity of cyclin T1-CDK9, cyclin B1-CDK1, cyclin E-CDK2, **cyclin D1-CDK4*, cyclin* E-CDK3, and p35-CDK5 with IC₅₀s of 1, 2, 3, 4, 5 and 5 nM, respectively; also inhibits GSK-3β, TAK1, Jak2 and MEK1, with IC₅₀s of 3, 5, 50, and 54 nM.

HY-10969

Obatoclax Mesylate GX15-070 Mesylate	Bcl-2 Family Autophagy Parasite	Cancer Infection
Obatoclax Mesylate (GX15-070 Mesylate), a BH3 mimetic, is a pan-BCL-2 family proteins inhibitor with a K_i of 220 nM for BCL-2. Obatoclax Mesylate induces autophagy-dependent cell death and targets cyclin D1 for proteasomal degradation. Obatoclax Mesylate has anti-cancer and broad-spectrum antiparasitic activity.

HY-10969A

Obatoclax GX15-070	Bcl-2 Family Autophagy Parasite	Cancer Infection
Obatoclax (GX15-070), a BH3 mimetic, is a pan-BCL-2 family proteins inhibitor with a K_i of 220 nM for BCL-2. Obatoclax induces autophagy-dependent cell death and targets cyclin D1 for proteasomal degradation. Obatoclax has anti-cancer and broad-spectrum antiparasitic activity.

HY-N1930

(-)-Hinesol Hinesol	Apoptosis	Cancer
(-)-Hinesol (Hinesol) is a potent anticancer agent. (-)-Hinesol induces apoptosis and cell cycle arrest at G0/G1 phase. (-)-Hinesol downregulates MEK/ERK pathway and NF-κB pathway and mediates theexpression of cyclin D1, Bax and Bcl-2. (-)-Hinesol has the potential for the research of non–small cell lung cancer.

HY-100900

ML364	Deubiquitinase	Cancer
ML364 is a selective ubiquitin specific peptidase 2 (USP2) inhibitor (IC₅₀=1.1 μM) with anti-proliferative activity, which direct binds to USP2 (K_d=5.2 μM), induces an increase in cellular cyclin D1 degradation and causes cell cycle arrest. ML364 increases the levels of mitochondrial ROS and decreases in the intracellular content of ATP.

HY-N6954

Garcinone C	ATM/ATR STAT CDK	Cancer
Garcinone C, a xanthone derivative, is a natural compound extracted from Garcinia oblongifolia that is used as an anti-inflammatory, astringency and granulation-promoting medicine, and has potential cytotoxic effects on certain cancers. Garcinone C stimulates the expression levels of ATR and 4E-BP1, while efficiently inhibiting the expression levels of cyclin B1, cyclin D1, cyclin E2, cdc2, Stat3 and CDK7. Garcinone C significantly inhibits cell viability of the human Nasopharyngeal carcinoma (NPC) cell lines CNE1, CNE2, HK1 and HONE1 in a time‑ and dose‑dependent manner.

HY-N6953

Garcinone D	STAT Keap1-Nrf2 Reactive Oxygen Species	Neurological Disease
Garcinone D, a natural xanthone from mangosteen, promotes the proliferation of C17.2 neural stem cell. Garcinone D increases the protein levels of phosphorylated signal transducer and activator of transcription 3 (p-STAT3), Cyclin D1 and nuclear factor erythroid 2-related factor (Nrf2), heme oxygenase-1 (HO-1) in concentration- and time- dependent manners.

HY-18981

Decursin (+)-Decursin	PKC Apoptosis CXCR	Cancer Inflammation/Immunology Neurological Disease
Decursin ((+)-Decursin) is a potent anti-tumor agent. Decursin also is a cytotoxic agent and a potent protein kinase C activator. Decursin induces apoptosis and cell cycle arrest at G1 phase. Decursin decreases the expression of CDK2, CDK4, CDK6, cyclin D1 protein at 48 h. Decursin inhibits cell proliferation and migration. Decursin shows anti-tumor, anti-inflammatory and analgesic activities.

HY-150597

HDAC-IN-46	HDAC Apoptosis	Cancer
HDAC-IN-46 (compound 12c) is a potent HDAC inhibitor with an IC₅₀ value of 0.21 μM and 0.021 μM for HDAC1 and HDAC6, respectively. HDAC-IN-46 upregulates p-p38, and downregulates Bcl-xL and cyclin D1 in MDA-MB-231 cells. HDAC-IN-46 induces significant G2 phase arrest and apoptosis. HDAC-IN-46 can be used for researching triple-negative breast cancer (TNBC).

HY-107738

Guggulsterone Z/E-Guggulsterone	Apoptosis JNK Akt Caspase FXR Autophagy	Cancer
Guggulsterone is a plant sterol derived from the gum resin of the tree Commiphora wightii. Guggulsterone inhibits the growth of a wide variety of tumor cells and induces apoptosis through down regulation of antiapoptotic gene products (IAP1, xIAP, Bfl-1/A1, Bcl-2, cFLIP and survivin), modulation of cell cycle proteins (cyclin D1 and c-Myc), activation of caspases and JNK, inhibition of Akt. Guggulsterone, a farnesoid X receptor (FXR) antagonist, decreases CDCA-induced FXR activation with IC₅₀s of 17 and 15 μM for Z- and E-Guggulsterone, respectively.

HY-149911

GY1-22
MDM-2/p53 Cancer

GY1-22 is an inhibitor of DNAJA1-mutP53^R175H interacting pocket. GY1-22 can be used for the research of cancer.

GY1-22	MDM-2/p53	Cancer
GY1-22 is an inhibitor of DNAJA1-mutP53^R175H interacting pocket. GY1-22 can be used for the research of cancer.

HY-151898

CDK4/6-IN-14	CDK	Cancer
CDK4/6-IN-14 is a potent and highly selective CDK4 and CDK6 (CDK) inhibitor with IC₅₀s of 10 nM and 16 nM, respectively. CDK4/6-IN-14 exhibits more than 60-fold selectivity over CDKs 1, 2, 7, and 9, and shows high selectivity among other 205 kinases.

HY-N3825

ent-Kaurane-3α,16β,17-triol
Apoptosis Cancer

ent-Kaurane-3α,16β,17-triol (Compound 3) is an anticancer agent. ent-Kaurane-3α,16β,17-triol induces apoptosis in HCT116 cells.

ent-Kaurane-3α,16β,17-triol	Apoptosis	Cancer
ent-Kaurane-3α,16β,17-triol (Compound 3) is an anticancer agent. ent-Kaurane-3α,16β,17-triol induces apoptosis in HCT116 cells.

HY-19831A

(Z)-4EGI-1	Eukaryotic Initiation Factor (eIF)	Cancer
(Z)-4EGI-1 is the Z-isomer of 4EGI-1 and is an inhibitor of eIF4E/eIF4G interaction and of translation initiation. (Z)-4EGI-1 effectively binds to eIF4E with an IC₅₀ of 43.5 μM and a K_d value of 8.74 μM. (Z)-4EGI-1 has anticancer activity.

HY-N10670

Bursehernin Methylpluviatolide	Apoptosis	Cancer
Bursehernin (Methylpluviatolide) is an antitumor agent. Bursehernin induces Apoptosis and cell cycle arrest at G2/M phase. Bursehernin shows anti-proliferative activity.

HY-123847

KPT-6566	Others	Cancer
KPT-6566 is a selective and covalent prolyl isomerase PIN1 inhibitor, covalently binds to the catalytic site of PIN1, selectively inhibits and degrades PIN1. KPT-6566 shows an IC₅₀ value of 640 nM and a K_i value of 625.2 nM for PIN1 PPIase domain. KPT-6566 can be used for the research of cancer.

HY-15128

9-cis-Retinoic acid Alitretinoin	RAR/RXR Apoptosis Endogenous Metabolite	Cancer Inflammation/Immunology Neurological Disease
9-cis-Retinoic acid (ALRT1057), a vitamin A derivative, is a potent RAR/RXR agonist. 9-cis-Retinoic acid induces apoptosis, regulates cell cycle and has anticancer, anti-inflammatory and neuroprotection activities.

Cat. No.	Product Name	Target	Category